Recent advances in the field of tumor immunology highlight the difficulties involved in generating and maintaining a tumor-specific immune response. The tendency of T cells to be tolerized in vivo, and the tendency of tumors to escape immune recognition represent significant barriers to successful immunotherapy. The results of early clinical trials illustrate these points and underscore the critical importance of an interactive dialog between laboratory and clinical research efforts.
展开▼
